Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Sasso

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
BMC Geriatrics|August 23, 2025
Syncope is associated with multidimensional frailty in older adultsFrancesco Curcio, Rosaria Chiappetti, Pietro Medio, et al.
Aging Clinical and Experimental Research|January 4, 2020
Type 2 myocardial infarction: is it a geriatric syndrome?Francesco Curcio, Gerardo Gerundo, Giuseppe Sasso, et al.
Journal of Medical Imaging and Radiation Oncology|June 21, 2023
Patterns of practice regarding use of radiation therapy following radical prostatectomy: A survey of Radiation Oncologists and Urologists in Australia and New ZealandAnna Lawless, Andrew Kneebone, Shreya Armstrong, et al.
BMC Cancer|March 6, 2016
A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)Shankar Siva, Tomas Kron, Mathias Bressel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2023
Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary OligometastasesShankar Siva, Pitchaya Sakyanun, Tao Mai, et al.
JAMA Oncology|August 29, 2021
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical TrialShankar Siva, Mathias Bressel, Tao Mai, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
BMC Geriatrics|August 23, 2025
Syncope is associated with multidimensional frailty in older adultsFrancesco Curcio, Rosaria Chiappetti, Pietro Medio, et al.
Aging Clinical and Experimental Research|January 4, 2020
Type 2 myocardial infarction: is it a geriatric syndrome?Francesco Curcio, Gerardo Gerundo, Giuseppe Sasso, et al.
Journal of Medical Imaging and Radiation Oncology|June 21, 2023
Patterns of practice regarding use of radiation therapy following radical prostatectomy: A survey of Radiation Oncologists and Urologists in Australia and New ZealandAnna Lawless, Andrew Kneebone, Shreya Armstrong, et al.
BMC Cancer|March 6, 2016
A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)Shankar Siva, Tomas Kron, Mathias Bressel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2023
Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary OligometastasesShankar Siva, Pitchaya Sakyanun, Tao Mai, et al.
JAMA Oncology|August 29, 2021
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical TrialShankar Siva, Mathias Bressel, Tao Mai, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
Pageof 3